Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 289

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Linezolid resistance in clinical isolates of Staphylococcus aureus

Open access
Wilson, P.·2003·Journal of Antimicrobial Chemotherapy

Abstract

Sir, Linezolid is the first oxazolidinone antibiotic to be licensed for treatment of Gram-positive infections. It is active against methicillin-resistant Staphylococcus aureus (MRSA), glycopeptide-intermediate S. aureus (GISA) and vancomycin-resistant enterococci (VRE).1 It inhibits the formation of the initiation complex formed with mRNA, fMet-tRNA and the 30S ribosomal subunit. Mutations to the central loop of domain V of 23S rRNA have been associated with resistance to linezolid in several species in vitro.2 There has been one report of resistance of MRSA in a clinical infection, a patient with dialysis-related peritonitis.3 We report a second clinical infection due to a resistant MRSA, but unlike the earlier case this was shown to have developed from a susceptible isolate during treatment. A 52-year-old man underwent thoracotomy and drainage of right-sided empyema. On day 20 post-operation, MRSA susceptible to linezolid was isolated from sputum culture, empyema drain fluid and the thoracic drain site. The patient was treated with linezolid 600 mg 12 hourly for 21 days (intravenously then by mouth) as part of a clinical trial. Three weeks after completion of linezolid, MRSA, resistant to linezolid on British Society for Antimicrobial Chemotherapy (BSAC) disc testing, was isolated from a wound swab of the drain site and the empyema fluid. The thoracic drain was removed and the patient was treated with teicoplanin and rifampicin with good clinical response. Eleven isolates of MRSA from this patient were collected during his hospital stay and tested in parallel by BSAC disc testing, Etest methodology (AB Biodisk, Solna, Sweden) and NCCLS broth microdilution testing. BSAC disc testing was performed on Iso-Sensitest agar (ISA, Oxoid, Basingstoke, UK).4 In accordance with the trial protocol, linezolid susceptibility was determined using 30 µg linezolid discs and a zone diameter of ≥18 mm. Etest was performed on Mueller–Hinton agar with 2% sodium chloride using a 0.5 McFarland standard inoculum. Isolates with an MIC ≤ 4.0 mg/L by this method are considered susceptible to linezolid, and isolates with an MIC ≥ 8.0 mg/L are resistant. NCCLS broth microdilution methodology was used to determine susceptibility to linezolid and three other antimicrobials, erythromycin, teicoplanin and vancomycin. MICs were determined using the NCCLS broth microdilution method in cation-adjusted Mueller–Hinton broth (Trek Diagnostic Systems Ltd, East Grinstead, UK) with an inoculum of 3–7 × 104 cfu contained in 100 µL of medium. After incubation for 16–24 h (24 h for vancomycin) MIC endpoints were read. The clonal relationship between the isolates was examined using phage typing (Dr B. Cookson, Staphylococcal Reference Laboratory, Central Public Health Laboratory, Colindale, London, UK) and by pulsed-field gel electrophoresis (PFGE) of SmaI-macrodigested genomic DNA. Alleles 1, 2 and 4–6 of the 23S rRNA gene were amplified using a reverse primer common to each allele (SA23SR, 5′-GATCTTATAACCGAAGTTGGG-3′) and a primer unique to the sequence ∼3 kb upstream of each allele (SA23S5K1, 5′-CGCCTATGGATGGCATTGG-3′; SA23S5K2, 5′-AGCATCTGCCTTACAAGCAG-3′; SA23S5K4, 5′-GTAGCTTTAGATGTTCATACG-3′; SA23S5K5, 5′-GGTAATGGCATAAATTGTG AC-3′; SA23S5K6, 5′-AGAACATTCTAACTACGGAAG-3′). Allele 3 was amplified using a reverse primer ∼3 kb downstream of the allele (SA23S5K3R, 5′-TGCTACCGCGCCTGCTTC-3′) and a primer (SA23S5K3, 5′-CACTCACAAGATTAATAACGC-3′) immediately upstream of the allele. Amplified products were sequenced using five primers covering the complete 23S rRNA gene sequence (SA23SseqR1, 5′-TTGTAAGCACACGGTTTCAG-3′; SA23SseqF1, 5′-GCCCAAACCAACAAGCTTGC-3′; SA23SseqF2, 5′-CAGACAAACTCCGAATGCC-3′; SA23SseqF3, 5′-GAAGACATTGAGTCTTCGAG-3′; SA23SseqF4, 5′-ACTACCCTAGCTGTGTTGGC-3′). Nucleotide sequences were aligned using the Clustal method with EditSeq and MegAlign software (DNASTAR, Madison, WI, USA). The MIC of linezolid for the MRSA was 2 mg/L during treatment. The linezolid-resistant isolate was first detected in a sample 20 days after linezolid treatment finished (Table 1). There were separate populations of MRSA with some colonies that were linezolid susceptible (MIC 1.0–2.0 mg/L by Etest) and others linezolid resistant (MIC 8.0–32.0 mg/L). Empyema fluid on day 71 post-operation contained both linezolid-susceptible and -resistant strains, which were resistant and susceptible to erythromycin, respectively. All isolates were susceptible to gentamicin, rifampicin, tetracycline, fusidic acid and trimethoprim, and resistant to ciprofloxacin. Phage typing of the susceptible and resistant isolates showed them to be indistinguishable E-MRSA 15 (Dr B. Cookson). All isolates had identical banding patterns on PFGE. Sequencing of the resistant isolates demonstrated a G2576T (Escherichia coli numbering) mutation in domain V of 23S rRNA genes compared with susceptible isolates and the S. aureus reference sequence (GenBank accession number X68425). An isolate with an MIC

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/jac/dkg104

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 289

Metadata

Authors
Wilson, P.
Venue
Journal of Antimicrobial Chemotherapy
Published
2002-12-12
Volume
51
Issue
1
Pages
186-188
ISSN
  • 0305-7453 (ISSN-L)
  • 1460-2091
OpenAlex
W2098651487
Cited by
289
References
3
FWCI
12.63
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Linezolid resistance in clinical isolates of Staphylococcus aureus. https://app.cochat.ai/papers/10.1093/jac/dkg104
The paper
Wilson, P. (2003). Linezolid resistance in clinical isolates of Staphylococcus aureus. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkg104

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.